No profile data available.
Context Therapeutics Inc. (CNTX) is a healthcare company in the additional cancer treatment drugs industry, based in Philadelphia, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$36.12 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $27.95 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Context Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$27.95 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Cel-sci Corporation (CVM), NextCure, Inc. (NXTC), TransCode Therapeutics, Inc. (RNAZ), Intensity Therapeutics, Inc. (INTS).